"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Hold on to your huaraches: as ...

What You Need to Know: Russia's T-90M "Proryv-3" tank, once highly touted as a battlefield breakthrough, has struggled in Ukraine, underscoring broader issues in Russia’s military-industrial ...

If you complete War Thunder's "Dreams Come True" event, you'll pick up a decoration, two decals, and a new tank to add to your arsenal. The KV-7 Soviet tank destroyer first appeared in 1941 and sports ...

Elevate your golf game with this Lilly ... Pulitzer skort in a vibrant pink hue, offering UPF 50 protection and stylish comfort for your time on the course. Embrace a breezy vibe with this smocked ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment ...

Copyright 2024 The Associated Press. All Rights Reserved. FILE - This April 26, 2017 file photo shows the Eli Lilly & Co. corporate headquarters in Indianapolis. (AP ...

Drug maker Eli Lilly’s share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare ...

Eli Lilly (NYSE:LLY) shares fell ~9% in the premarket on Wednesday, sending ADRs of its rival Novo Nordisk (NVO) lower after the U.S. drugmaker missed Street forecasts with its Q3 2024 financials ...

Shares of Eli Lilly and Co. slumped toward their biggest selloff in more than three years on Wednesday, after the drugmaker reported third-quarter results that missed expectations, due to big ...

Eli Lilly reported Q3 revenue and earnings that fell short of analysts' expectations. Mounjaro and Zepbound faced challenges as U.S. wholesalers reduced inventories of the drugs. The bull case for ...

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule. Lilly kicked DC ...